Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 4Primary Myelofibrosis 3Thrombocythemia, Essential 1Polycythemia Vera 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1

Interventions

fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Cyclophosphamide 2Busulfan 2Azacitidine 2venetoclax 1pevonedistat 1fludarabine 1fedratinib 1Valganciclovir 1Transplantation 1Therapeutics 1Sirolimus 1Radiotherapy 1Positron-Emission Tomography 1Polymerase Chain Reaction 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Methotrexate 1Melphalan 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Etoposide 1Cyclosporine 1Antiviral Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Neutrophilic, Chronic × fedratinib × 1 year × Clear all
NCT05177211 2026-04-17

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Neutrophilic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡